AstraZeneca PLC (LSE:LON:AZN), the global biopharmaceutical company, announced on Monday that as of August 31, 2024, its issued share capital comprised 1,550,286,637 ordinary shares with voting rights, each share with a nominal value of US$0.25. The company confirmed that no shares are currently held in treasury, which means the total number of voting rights in the company is the same as the number of shares.
This update complies with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. AstraZeneca (NASDAQ:AZN) highlighted that the total number of voting rights is a key figure for shareholders to determine whether they must notify their interest in, or a change to their interest in, the company under the Disclosure and Transparency Rules.
AstraZeneca, headquartered in Cambridge, UK, specializes in the discovery, development, and commercialization of prescription medicines, focusing on areas such as Oncology, Rare Diseases, and BioPharmaceuticals, which includes Cardiovascular, Renal & Metabolism, and Respiratory & Immunology therapies. The company operates on a global scale, with its products being available in over 125 countries and utilized by millions of patients worldwide.
The company's commitment to innovation and its presence in the pharmaceutical industry is underscored by its extensive global outreach and the impact of its medicines on patient health.
The information provided is based on a press release statement.
In other recent news, AstraZeneca's IMFINZI (durvalumab) has received U.S. Food and Drug Administration (FDA) approval for treating adults with resectable early-stage non-small cell lung cancer (NSCLC). This approval is based on the AEGEAN Phase III trial results, which indicated a significant reduction in disease recurrence risk.
In addition, IMFINZI has been granted Priority Review status by the FDA for the treatment of limited-stage small cell lung cancer, following successful results from the ADRIATIC Phase III trial.
In financial developments, AstraZeneca secured €1.4 billion through a bond offering managed by BNP Paribas (OTC:BNPQY), Goldman Sachs (NYSE:GS) International, Morgan Stanley (NYSE:MS), and Société Générale. TD Cowen expressed confidence in AstraZeneca, raising its stock price target on the company's shares to $95 from the previous target of $90, while maintaining a Buy rating.
These recent developments highlight AstraZeneca's ongoing achievements in the pharmaceutical industry. The company continues to focus on novel approaches in early lung cancer treatment, to improve patient outcomes and survival rates.
InvestingPro Insights
AstraZeneca PLC (LSE:AZN) continues to draw attention in the biopharmaceutical sector, not only for its share capital and voting rights but also for its financial metrics and market performance. According to real-time data from InvestingPro, the company boasts a substantial market capitalization of approximately $269.52 billion. With a P/E ratio standing at 41.82, the company exhibits a valuation that may be considered high relative to its near-term earnings growth. This is further illustrated by a PEG ratio (which measures the P/E relative to the growth rate) of 9.83, suggesting that investors are paying a premium for anticipated growth.
InvestingPro Tips point out that AstraZeneca is trading at a high Price / Book multiple of 6.82, indicating that the market values the company significantly above its book value. Additionally, the company has been a reliable dividend payer, having maintained payments for 32 consecutive years, a testament to its financial resilience and commitment to shareholder returns. Among the 17 additional tips available on InvestingPro, investors might be interested to note that AstraZeneca is perceived as a prominent player in the Pharmaceuticals industry and has experienced a large price uptick over the last six months. Such insights can be pivotal for investors considering AstraZeneca's stock, especially in light of the company's global impact and innovative drive.
For those seeking a deeper analysis of AstraZeneca's financial health and future prospects, further InvestingPro Tips are accessible, which could provide valuable guidance in making informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.